As the pharmaceutical industry searches for new ways to accelerate drug discovery, access to high quality molecular data is becoming a critical bottleneck. Paris based biotech company Generare is addressing this challenge by exploring an untapped source of chemical diversity found in microbial genomes. The company has now raised €20 million in Series A funding to expand its platform and scale its data driven approach to drug development.
Strong Support from Leading Investors
The funding round was co led by Alven and Daphni, with participation from existing investors including Galion.exe, Teampact Ventures, and VIVES Partners.
This investment reflects growing confidence in Generare’s approach to expanding the molecular building blocks available for drug discovery. The capital will support further development of its platform, expansion of its compound library, and growth of its multidisciplinary team.
Expanding the Chemical Space for Drug Discovery
Drug discovery has traditionally been limited to a relatively narrow chemical space, largely due to constraints in available data. This limitation has restricted the ability of researchers to identify new compounds with therapeutic potential.
Generare is working to overcome this challenge by tapping into microbial genomes, which contain a vast and largely unexplored reservoir of molecular diversity. These genomes have evolved over billions of years, offering a rich source of novel compounds that could be used in medicine.
By decoding and characterising this biological data, the company aims to significantly expand the range of molecules available for pharmaceutical research.
Building a Large Scale Molecular Dataset
Founded in 2023 by Guillaume Vandenesch and Vincent Libis, Generare is focused on creating a comprehensive dataset of small molecules derived from microbial sources.
Small molecules are a cornerstone of modern medicine, forming the basis of many widely used drugs. Each new molecule identified by Generare contributes to an expanding dataset that can be used by researchers and pharmaceutical companies.
The company’s platform integrates high throughput cloning and sequencing technologies to identify, express, and analyse bioactive compounds. This process generates structured data on the properties and potential applications of each molecule, making it easier to incorporate them into drug development pipelines.
Addressing a Key Industry Constraint
According to CEO Guillaume Vandenesch, one of the major limitations in drug discovery today is the lack of novel and high quality molecular data. Without access to diverse and well characterised compounds, researchers face challenges in developing effective treatments.
Generare’s approach aims to fill this gap by systematically generating and organising new molecular data at scale. This not only expands the available chemical space but also enhances the effectiveness of computational models and research methodologies used in drug discovery.
Growing Adoption and Industry Interest
The company reports increasing adoption of its platform among pharmaceutical and research organisations. Newly identified molecules are already being used in early stage drug development, demonstrating the practical value of its data driven approach.
As demand for innovative drug discovery solutions continues to grow, Generare is positioning itself as a key provider of high quality molecular data.
Scaling for the Future of Medicine
With the new funding, Generare plans to accelerate the expansion of its compound library and scale its discovery platform. The company will also invest in growing its team across multiple disciplines, including biology, chemistry, and data science.
By combining advanced biotechnology with large scale data generation, Generare is helping to redefine how new medicines are discovered. Its work has the potential to unlock previously inaccessible areas of chemical space, paving the way for the development of next generation therapeutics.
As the pharmaceutical industry continues to evolve, access to diverse and reliable molecular data will be essential. Generare’s innovative approach positions it at the forefront of this transformation, offering new possibilities for drug discovery and healthcare advancement.